Kuros Biosciences AG, a Swiss biotechnology company headquartered in Schlieren, has been making significant strides in the health care sector, particularly in the field of orthobiologics. Specializing in the development of products for tissue repair and regeneration, Kuros Biosciences AG focuses on addressing bony defects within the human skeletal system and enhancing bone formation at injury sites. The company’s innovative approach to orthobiologics positions it as a key player in the biotechnology industry, operating across both the United States and Europe.
As of May 26, 2026, Kuros Biosciences AG’s stock was trading at a close price of 21.66 CHF on the SIX Swiss Exchange. This represents a notable fluctuation within the year, with the stock reaching a 52-week high of 34.2 CHF on October 19, 2025, and a 52-week low of 18.7 CHF on May 12, 2026. The company’s market capitalization stands at 864,590,000 CHF, reflecting its substantial presence in the biotechnology sector.
Despite its promising product offerings and strategic market positioning, Kuros Biosciences AG’s financial metrics indicate a high ratio price earnings (P/E) of 381.015. This elevated P/E ratio suggests that investors have high expectations for the company’s future growth and profitability, potentially driven by its innovative product pipeline and expansion into key markets.
Kuros Biosciences AG’s commitment to advancing orthobiologic solutions is evident in its product development efforts aimed at filling bony defects and stimulating bone formation. These products are designed to meet critical needs in the medical field, offering potential improvements in patient outcomes and recovery times. The company’s dual presence in the United States and Europe allows it to leverage diverse market opportunities and regulatory environments, further enhancing its growth prospects.
For more detailed information about Kuros Biosciences AG’s products, services, and corporate developments, stakeholders and interested parties are encouraged to visit the company’s official website at www.kuros.ch . As a publicly traded entity on the SIX Swiss Exchange, Kuros Biosciences AG continues to attract attention from investors and industry observers alike, underscoring its role as a significant contributor to the biotechnology landscape.
